Bayer share price rise after turn in Roundup case

Bayer's share rose 11% on the New York Stock Exchange on Thursday, October 5. The reason for this was the message that the company may be given a second chance in the Roundup lawsuit. The evidence used would not suffice, a judge in San Francisco reported.

Roundup (or glyphosate) is a Monsanto product. However, that company has since been taken over by Bayer† The lawsuit concerns a former gardener in the United States. This man claims he got lymphoma from taking Roundup.

Many fines 
The jury then ruled that Monsanto had to reach out and fined the company $289 million. However, it is not just about that one ruling, because many fines can follow in similar cases. There are currently more than 8.700 similar claims that glyphosate has caused cancer. However, Monsanto continues to insist that Roundup is safe. 

The fact that the lawsuit may need to be re-heard sent a positive signal to investors. Despite the positive signal for the time being, analysts warn that the outcome of the legal battle is still highly uncertain.

Anne-Jan Doorn

Anne Jan Doorn is an arable expert at Boerenbusiness. He writes about the various arable farming markets and also focuses on the land and energy market.

aj.doorn@boerenbusiness. Nl

© DCA Market Intelligence. This market information is subject to copyright. It is not permitted to reproduce, distribute, disseminate or make the content available to third parties for compensation, in any form, without the express written permission of DCA Market Intelligence.